Peptide Synthesis CMO Research: the global market size is projected to reach USD 7.2 billion by 2031

QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Peptide Synthesis CMO- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Peptide Synthesis CMO market, including market size, share, demand, industry development status, and forecasts for the next few years.

The global market for Peptide Synthesis CMO was estimated to be worth US$ 3513 million in 2025 and is projected to reach US$ 8215 million, growing at a CAGR of 12.7% from 2026 to 2032.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5544827/peptide-synthesis-cmo

Peptide Synthesis CMO Market Summary

Peptides, as unique drug compounds, lie between small molecules and proteins, but differ in biochemistry and therapy. They offer opportunities for therapeutic interventions that closely mimic natural pathways and play a major role in various physiological processes in the human body, including hormones and neurotransmitters, or in inflammatory responses. Peptides can be extracted naturally or synthesized artificially, and their high purity and controllable quality have made them popular drugs. Small molecule drugs rarely possess the high selectivity and rapid onset of action of peptides.

A Peptide Synthesis CMO (Contract Manufacturing Organization) is a specialized third-party manufacturer that provides custom and large-scale peptide production services for pharmaceutical, biotechnology, and research companies under contract. These organizations offer end-to-end or modular services covering peptide design support, solid-phase and liquid-phase synthesis, peptide-drug conjugate and modified peptide production, purification (e.g., preparative HPLC), lyophilization, analytical characterization, and GMP or non-GMP manufacturing according to the client's development stage. Peptide Synthesis CMOs operate under stringent quality systems and regulatory standards, help sponsors reduce capital investment in internal manufacturing facilities, accelerate development timelines, and flexibly scale from milligram research batches to multi-kilogram commercial supply for APIs and peptide-based drug products.

The growth of the Peptide Synthesis CMO market is primarily driven by the rapid expansion of peptide therapeutics and the structural shift toward outsourcing. An increasing number of peptide drugs are being developed for metabolic disease, oncology, infectious disease and rare disorders, with more candidates entering clinical stages and requiring GMP-grade APIs and finished dosage forms. Sponsors prefer asset-light models and rely on specialized CMOs to provide end-to-end services-from route scouting and process development to large-scale manufacturing and aseptic fill-finish-so they can focus internal resources on discovery and clinical strategy. At the same time, the rising complexity of peptide molecules (long chains, cyclic and stapled structures, PEGylation, lipidation and conjugates) makes specialized equipment, advanced purification and sophisticated analytical methods indispensable, further reinforcing the role of highly capable CMOs. Integration of API and FDF capabilities, digitalization, automation, and green chemistry initiatives also act as important growth catalysts, enhancing efficiency, lowering cost of goods and aligning with big pharma's ESG and supply chain resilience requirements.

However, the market also faces significant challenges and restraints that can slow expansion and compress margins. Peptide manufacturing is intrinsically high-cost due to expensive protected amino acids, resins and solvents, and complex purification, while large pharma and well-capitalized biotechs exert strong price pressure and often dominate contract terms. Technical risk is substantial: difficult sequences and complex modifications can lead to low yields, high rates and project delays, especially for CMOs without deep scientific and analytical expertise. On top of this, increasingly stringent global regulations on impurities, nitrosamines, data integrity and GMP compliance raise the bar for quality systems and require continuous investment in equipment, IT and talent. Many players also struggle with capacity bottlenecks, dependence on a few major customers, and vulnerability to disruptions in key raw material supply. Together, these factors create a market where demand is structurally growing, but only CMOs that can manage cost, scale, regulatory complexity and technical risk simultaneously are likely to translate that demand into sustainable, profitable growth.

According to the new market research report "Global Peptide Synthesis CMO Market Report 2025-2031", published by QYResearch, the global Peptide Synthesis CMO market size is projected to reach USD 7.2 billion by 2031, at a CAGR of 12.4% during the forecast period.

The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.

The Peptide Synthesis CMO market is segmented as below:
By Company
Bachem
PolyPeptide
USV Peptides
Thermofischer
Bio Basic
JPT
Genscript
Medtide
ScinoPharm
AmbioPharm
SN Biopharm
CBL
Piramal Pharma
CordenPharma
CPC Scientific

Segment by Type
APIs and Intermediates
FDF

Segment by Application
Commercial
Academic Research
Other

Each chapter of the report provides detailed information for readers to further understand the Peptide Synthesis CMO market:

Chapter 1: Introduces the report scope of the Peptide Synthesis CMO report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of Peptide Synthesis CMO manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various Peptide Synthesis CMO market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of Peptide Synthesis CMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of Peptide Synthesis CMO in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Benefits of purchasing QYResearch report:

Competitive Analysis: QYResearch provides in-depth Peptide Synthesis CMO competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.

Industry Analysis: QYResearch provides Peptide Synthesis CMO comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.

and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.

Market Size: QYResearch provides Peptide Synthesis CMO market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.

Other relevant reports of QYResearch:
Global Peptide Synthesis CMO Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
Global Peptide Synthesis CMO Market Research Report 2026

About Us:
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

This release was published on openPR.